Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial
Gilead and Arcus announced that their anti-TIGIT antibody domvanalimab, combined with anti-PD-1 zimberelimab and chemotherapy, showed a median overall survival of 26.7 months in a Phase 2 gastric cancer trial.
The combination achieved a median progression-free survival of 12.9 months and an overall response rate of 59%.
The results have reignited interest in the anti-TIGIT modality, which previously faced setbacks.